Tomas J. Heyman

Tomas Heyman has been a member of their board of directors since September 2022. Mr. Heyman is a biopharmaceutical veteran with significant leadership and management expertise in corporate strategy, business development, venture capital, as well as R&D, legal and operational management, from his 37-year tenure with Johnson & Johnson (J&J). Mr. Heyman most recently served as president of JJDC, J&J’s corporate venture capital group, from April 2015 to September 2019, where he managed approximately $1.5 billion in capital and oversaw investments in more than 120 companies. Prior to leading JJDC, he led business development for J&J’s pharmaceutical group, Janssen, for twenty-three years, completing hundreds of licensing and M&A transactions. He also served as the managing director of Janssen Pharmaceutica, Belgium, J&J’s largest subsidiary outside the U.S., and vice president of licensing at Ortho Pharmaceutical, a J&J affiliate. Mr. Heyman serves as a member of the boards of directors of Legend Biotech, Akero Therapeutics, OptiNose, and Invivyd (formerly Adagio Therapeutics). Mr. Heyman received his Master of Law from K.U. Leuven in Belgium and completed post-graduate studies in international law in Geneva, Switzerland, and post-graduate studies in business management at the University of Antwerp in Belgium.